Nightingale reports fiscal 2013 fourth quarter and year end results

- Strong demand for Company's cloud-based EMR software fuels top line

MARKHAM, ON, July 24, 2013 /CNW/ - Nightingale Informatix Corporation ("Nightingale" or the "Company") (TSX-V: NGH), an application service provider (ASP) of electronic medical record (EMR) software and related services, announces its financial results for the three months and year ended March 31, 2013. All results are reported under International Financial Reporting Standards (IFRS) and are in Canadian dollars unless otherwise stated.

Q4 Fiscal 2013 Financial and Operational Summary

  • Revenue was $5.2 million, down 3% from $5.4 million in Q4 F2012, reflecting the Company's exit from its low margin revenue cycle management and transcription businesses.  Total Q4 revenue increased 2% from $5.1 million in Q3 F2013.
    • Total software revenue (EMR and Practice Management) was $5.1 million, up 3% from $5.0 million in Q4 F2012.
  • Gross profit was $4.7 million (or 91% of revenue), up 5% from $4.5 million (84% of revenue) in Q4 F2012.
  • Operating Expenses, excluding stock based compensation, depreciation and amortization were $4.3 million in each of Q4 F2013 and Q4 F2012.
  • Adjusted EBITDA1 was $1.0 million (20% of revenue), compared to $0.2 million (4% of revenue) in Q4 F2012.
  • Net income was $0.9 million in Q4 F2013, compared to a net loss of $0.2 million in Q4 F2012. Net income included a tax gain of $1.0 million resulting from the release of an unneeded tax provision and the recognition of benefit from previously unrecorded tax losses.
  • Cash used in operations was $0.7 million in Q4 F2013 compared to cash provided by operations of $1.4 million in Q4 F2012.
  • Revaluation of a derivative financial asset related to the Company's Series B convertible debenture resulted in a gain of $0.1 million, recorded as other financial gains.

Fiscal 2013 Financial and Operational Summary

  • Total revenue was $20.9 million, up 16% from $18.1 million in F2012, reflecting a significant 26% increase in software revenue to $20.6 million.
    • Software revenue increased from $16.3 million in FY2102 to $20.6 million in FY2013, an increase of 26%.
    • Recurring revenue from continued operations increased by 21% compared to F2012.
  • Gross profit was $18.6 million (or 89% of revenue), compared to $15.0 million (83% of revenue) in F2012.
  • Operating Expenses, excluding stock based compensation, depreciation and amortization were $15.5 million, up 9% from $14.3 million in F2012. Without business acquisition, integration and other costs, operating expenses were $14.8 million, compared to $13.8 million for F2012.
  • Adjusted EBITDA1 was $3.7 million (18% of revenue), compared to $1.3 million (7% of revenue) in F2012.
  • Net income was $2.0 million, compared to a net loss of $1.2 million for F2012. Net income included a tax gain of $0.7 million from the release of an unneeded tax provision and another $0.4 million from the recognition of the benefit from previously unrecorded tax losses.
  • Cash used in operations was $1.7 million, compared to cash provided by operations of $1.9 million in F2012.
  • Completed a $5.3 million financing through a Convertible Debenture Private Placement and the arrangement of a Senior Debt Facility in March 2013.
  • Appointed a new Chief Financial Officer, Peter Cauley, in April 2013.
  • Signed a $3.0 million five-year agreement with Giiwedong Health Link (GHL) in March 2013.

"Our efforts in 2013 have positioned our company well to benefit from the opportunities in the North American EMR market.  We have strengthened our balance sheet through our most recent financing as well as a near $1 million repayment of our Series A debenture, nearly completed the transformation into a pure-play technology company, successfully changed our sales strategy and strengthened our management team. As a result, we recorded our 17th consecutive quarter of positive EBITDA, with EBITDA growing to 18% of revenue, compared to 7% for the prior year," said Sam Chebib, President and CEO of Nightingale. "During the year we delivered on large projects, such as the AOHC deal, while dedicating resources to the enterprise sector, resulting in a number of important customer wins, this past quarter most notably with GHL."

Mr. Chebib added: "We anticipate launching Nexia, our next generation EMR platform, in the U.S. in the fall.  Initial feedback from Beta testing has shown us the game changing potential of this platform, and our enterprise team has built up a healthy long-term pipeline.  The launch of Nexia will also see Nightingale transition to a SaaS-based business model for the SMB market, a process we started subsequent to Q4.  Long-term, we believe the recurring revenue nature of the SaaS model will result in much greater predictability of the business, yield higher margins and create a platform for accelerated growth. However, this transition, combined with prospect enterprise clients holding off on making investments in EMR pending the commercial availability of Nexia, we anticipate will generate some revenue volatility in the coming quarters."

Fiscal 2013 Year End and Q4 Financial Review
Nightingale's F2013 and F2012 annual and Q4 results are prepared in accordance with IFRS. For more detailed information regarding the Company's financial results please refer to the Company's financial statements and MD&A filings on SEDAR at www.sedar.com.

Revenue for F2013 was $20.9 million, up 16% from $18.1 million for F2012, driven by a 26% increase in software revenue ($20.6 million for F2013, compared to $16.4 million in F2012). Growth in software sales was attributable in large part to the ongoing implementation of the Company's major EMR contract win with the AOHC in F2012, which contributed 15% of F2013 revenue. The Company generated 33% of F2013 revenue and 28% of Q4 F2013 revenue in US dollars.  Foreign exchange fluctuations had a minimal impact on revenue for F2013 and for Q4 F2013.

Revenue for Q4 F2013 was $5.2 million, down 3% from $5.4 million for Q4 F2012, attributable to the Company's gradual exit from its low-margin transcription business.

Recurring revenue2 for F2013 was $10.6 million (51% of revenue), compared to $10.2 million (56% of revenue) for F2012. The decrease was caused primarily by a reduction in Revenue Cycle Management (RCM) revenue, as the Company moved away from providing lower margin healthcare services. Recurring revenue from continued operations increased by 21% over F2012.  Recurring revenue for Q4 F2013 decreased 10% to $2.6 million (50% of revenue) from $2.9 million (54% of revenue) for Q4 F2012, primarily due to the year-over-year decline in RCM revenue.

Non-recurring revenue2 for F2013 was $10.3 million, up 31% from $7.9 million for F2012. Non-recurring revenue for Q4 F2013 was $2.6 million, up 4% from $2.5 million in Q4 F2012. Growth was largely the result of revenue related to the Company's significant EMR contracts with GHL, MCI and the AOHC.

For F2013, gross margin was 89% ($18.6 million gross profit) compared to 83% ($15.0 million gross profit) for F2012. For Q4 F2013, gross margin was 91% ($4.7 million gross profit) compared to 84% ($4.5 million gross profit) for Q4 F2012.

As a result of the Company's continued strategic investment in the business to support long-term growth initiatives, operating expenses for F2013 increased 9% to $15.5 million, excluding charges for stock based compensation and depreciation and amortization, or 8% to $14.8 million also excluding one-time business acquisition, integration and other one-time costs. This is compared to operating expenses of $14.3 million, excluding charges for stock based compensation and depreciation and amortization for F2012 and $13.7 million when you exclude one-time business acquisition, integration and other one-time costs . Operating expenses for Q4 F2013 and Q4 F2012 were $4.3 million excluding charges for stock based compensation and depreciation and amortization.

For F2013, adjusted EBITDA was $3.7 million compared to $1.3 million in F2012, reflecting the Company's increased revenue from its software business. For Q4 F2013, adjusted EBITDA was $1.0 million compared to $0.2 million for Q4 F2012.

For F2013, the Company recognized an income tax benefit resulting from the release of an unneeded tax provision and the recognition of the benefit from previously unrecorded tax losses.

For F2013, net income was $2.0 million, compared to a loss of $1.2 million in F2012. Net income was $0.9 million for Q4 F2013, compared to a net loss of $0.3 million in Q4 F2012.

Cash and cash equivalents were $3.5 million as at March 31, 2013, up from $3.2 million as at March 31, 2012, primarily as a result of the Company's financing completed in the fourth quarter, offset by increased investments in its long-term strategic growth initiatives.

In March 2013, the Company redeemed $925,000 of the Series A Debentures in exchange for investments in Series C and subsequent to year end, in the first quarter of F2014, the Company redeemed the remaining $1,141,000 of Series A Debentures.

At March 31, 2013, total common shares issued and outstanding were 76,310,915.

The financial statements and MD&A will be available at www.nightingalemd.com and filed on www.sedar.com on July 24, 2013.  This press release should be read in conjunction with Nightingale's Consolidated Financial Statements and the accompanying Management Discussion and Analysis for the year ended March 31, 2013.

Investor Relations Agreement
Nightingale has engaged Tekkfund Capital Corp. to assist the company with investor outreach. In connection with the engagement, Tekkfund has been awarded a consulting contract paying $6,000 per month for a term of three years, cancellable on thirty days' notice after the first year.  In relation to the agreement Tekkfund has been granted options to purchase 100,000 shares of Nightingale at a price of 23.5 cents ($0.235) per share for the first year of service.  Each subsequent year of the agreement, Tekkfund will receive additional options for the purchase of 100,000 shares.  The options will vest quarterly and will be governed by the provisions of Nightingale's stock option plan.

Notice of Conference Call
Nightingale will host a conference call on Wednesday, July 24, 2013, at 8:30 a.m. Eastern Standard Time. To access the conference call by telephone, dial (888) 231-8191 (or (647) 427-7450 for international). Please connect approximately fifteen minutes prior to the call, and reference conference ID 15748935 prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Wednesday, July 31, 2013. To access the archived conference call, dial 416-849-0833 or 1-855-859-2056 and enter reference 15748935#. To listen to the conference call replay on the internet please visit the Nightingale website shortly after the call at www.nightingalemd.com.

Non-IFRS Financial Measures
The Company internally measures its performance and results of initiatives through a number of measures that are not recognized under IFRS and may not be comparable to similar measures used by other companies.

1. Adjusted EBITDA
Adjusted EBITDA is a non-IFRS measure that management believes is a useful measurement to evaluate the performance of the Company. Investors should be cautioned, however, that Adjusted EBITDA should not be construed as an alternative to net earnings as determined in accordance with IFRS. The Company's method of calculating Adjusted EBITDA may differ from the methods used by other companies and, accordingly, it may not be comparable to similarly titled measures used by other companies.

Adjusted EBITDA is defined as earnings before other loss (income), interest, income taxes, depreciation, amortization, stock-based compensation, and business acquisition, integration and other costs. Management believes it is useful to exclude these items as they are either non-cash expenses, items that cannot be influenced by management in the short term, or items that do not impact core operating performance, and Management uses this information internally for forecasting and budgeting purposes.

The following provides a reconciliation of Adjusted EBITDA to Income (Loss) and Comprehensive Income (Loss):

         
  Quarter Ended Quarter Ended Fiscal Year
Ended
Fiscal Year
Ended
Definition March 31, 2013 March 31, 2012 March 31, 2013 March 31, 2012
                 
Income (Loss) and
Comprehensive Income (Loss)
$       892,659 $    (285,457) $     1,992,555 $    (1,218,396)
                 
Adjustments for:                
Current Tax Expense (Benefit)   (1,009,423) $         12,032   (1,079,452) $            18,514
Other Loss (Income)   (28,268)   (74,954)   (23.029)   (79,508)
Interest   232,079   108,247   537,598   466,509
Depreciation and Amortization   439,861   505,557   1,625,089   1,513,913
Stock-based Compensation   10,135   19,814   139,793   115,803
Other financing gain   (134,942)   (54,702)   (134,942)   (54,702)
Acquisition, Integration and Other   625,833   -   675,804   512,889
Adjusted EBITDA $   1,027,934 $      230,537 $    3,733,416 $      1,275,022

2. Recurring and Non-Recurring Revenue
The Company has included recurring revenue and non-recurring revenue measurements since it believes that this information is useful to investors to evaluate its performance. Investors should be cautioned, however, that recurring revenue and non-recurring revenue should not be construed as an alternative to revenue as determined in accordance with IFRS.  Recurring Revenue is comprised of utilization fees, hosting, support and maintenance revenue, data management and transcription services, billing and financial management services and transactional fees.  Non-Recurring Revenue is comprised of revenues generated from sales of perpetual software and systems licenses and related training, data conversion and installation services.

The following provides a reconciliation of Recurring Revenue and Non-Recurring Revenue to Revenue:

         
  Quarter Ended Quarter Ended Fiscal Year Ended Fiscal Year Ended
Definition March 31, 2013 March 31, 2012 March 31, 2013 March 31, 2012
Non-Recurring Revenue $ 2,593,780 $    2,486,361 $   10,324,405 $ 7,888,115
Recurring Revenue    2,605,505   2,889,396   10,600,447   10,192,269
                 
Revenue $   5,199,285 $    5,375,757 $   20,924,852 $        18,080,384

About Nightingale
Nightingale is one of the fastest growing health care service and software companies in North America and is recognized as an industry leader in Web-based clinician and community based electronic medical records (EMR) serving the needs of small primary care practices, multi-physician outpatient clinics, and large scale regional health organizations and networks. Coupled with integrated practice management, transcription and revenue cycle management, Nightingale's comprehensive service offering allows customers to enhance patient care, increase revenue opportunities and optimize operations. Nightingale is continuously innovating and enhancing its services to meet the needs of its growing and diverse customer base. Nightingale - Healthcare connected. www.nightingalemd.com

Forward Looking Statement
This press release contains "forward-looking statements" respecting the issuance and cancellation of securities of the Company within the meaning of applicable Canadian securities legislation. Generally, forward-looking statements can be identified by the use of forward- looking terminology such as "plans", "expects" or "does not expect",  "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may" ,"could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Nightingale to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the speculative nature of the medical software industry, which is affected by numerous factors beyond Nightingale's control; the ability of Nightingale to successfully secure customer contracts and the timing of securing such contracts; the ability of Nightingale to complete and successfully integrate its acquisitions on an accretive basis, Nightingale's access to debt and capital facilities, including compliance with current debt arrangements; the existence of present and possible future government regulation; the significant competition that exists in the medical software industry; the early stage of Nightingale's business, and risks associated with early stage companies, including uncertainty of revenues, markets and profitability and the need to raise additional funding.  All material assumptions used in making forward-looking statements are based on management's knowledge of current business conditions and expectations of future business conditions and trends. Certain material factors or assumptions applied by management in making forward-looking statements, include without limitation, factors and assumptions regarding future trends in healthcare spending, economic conditions affecting Nightingale and North American economies; Nightingale's ability to continue to fund its business, rates of customer defaults, relationships with, and payments to lenders, as well as Nightingale's operating cost structure.

Although Nightingale has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Nightingale does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities laws. Further information on Nightingale Informatix Corporation is available at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE TWELVE MONTHS ENDED MARCH 31, 2013 and MARCH 31, 2012


  March 31, 2013     March 31, 2012
             
             
Revenue $    20,924,852     $    18,080,384 
             
Cost of sales   2,342,467       3,050,782
             
Gross profit   18,582,385       15,029,602
             
Expenses            
General and administration   3,489,350       3,351,479
Sales and marketing   3,366,065       3,291,377
Research and development   5,500,278       4,433,611
Client services   4,258,158       4,307,829
Business acquisition, integration and            
  other   675,804       512,889
    17,289,655       15,897,185
             
Operating income (loss)   1,292,730       (867,583)
             
Interest   537,598       466,509
Other financing gain   -       (54,702)
Foreign currency gain   (23,029)       (79,508)
             
Income (loss) before tax   913,103       (1,199,882)
Current tax benefit (expense)   1,079,452       (18,514)
             
Net Income (loss) and comprehensive income (loss) $      1,992,555     $            (1,218,396)
             
Basic and diluted net income (loss) per common share            
             
Net income (loss) per common share - basic $              0.03     $           (0.02)
Net income (loss) per common share - diluted $            0.03     $          (0.02)
             
Weighted average number of common shares - basic   76,310,915       76,310,915
Weighted average number of common shares - diluted   92,882,264       76,310,915

CONSOLIDATED BALANCE SHEET
AS AT MARCH 31, 2013 and MARCH 31, 2012

      March 31, 2013     March 31, 2012    
               
ASSETS              
               
Current assets              
Cash and cash equivalents $ 3,491,780   $ 3,199,058    
Accounts receivable and unbilled accounts receivable   5,820,214     2,267,854    
Other receivables   196,127     103,513    
Prepaid expenses   415,958     581,593    
    9,924,079     6,152,018    
               
Long-term assets              
Unbilled accounts receivable   339,752     -    
Financial asset   808,694     -    
Property and equipment   857,270     450,989    
Intangible assets   7,974,606     5,808,744    
Goodwill   4,792,399     4,792,399    
    14,772,721     11,052,132    
               
Total assets $ 24,696,800   $ 17,204,150    
               
LIABILITIES              
               
Current liabilities              
Line of credit $ 1,000,000   $ 670,000    
Accounts payable and accrued liabilities   4,271,996     3,351,187    
Current portion of deferred revenue   4,176,876     4,689,175    
Current portion of finance lease obligations   64,397     122,710    
Current portion of convertible debentures   1,064,4280     -    
Current portion of term loan   1,521,720     872,813    
    12,099,417     9,705,885    
               
Long term liabilities              
Term loan   2,686,704     2,287,608    
Convertible debentures   5,353,050     1,802,256    
Deferred revenue   1,713,326     2,619,448    
Finance lease obligations   36,739     37,345    
Income taxes payable   -     686,921    
    9,789,819     7,433,578    
               
Total liabilities   21,889,236     17,139,463    
               
SHAREHOLDERS' EQUITY              
Capital stock   29,629,683     29,629,683    
Contributed surplus   5,781,073     4,811,456    
Equity portion of convertible debentures   811,558     333,808    
Warrants   4,407     701,452    
Deficit   (33,419,157)     (35,411,712)    
    2,807,564     64,687    
               
Total liabilities and shareholders' equity $ 24,696,800   $ 17,204,150    
               

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE TWELVE MONTHS ENDED MARCH 31, 2013 and MARCH 31, 2012

             
  March 31, 2013     March 31, 2012
             
Cash flow from operating activities            
Income (loss) from operations $ 1,992,555     $ (1,218,396)
             
Adjustments for:            
Depreciation and amortization   1,625,089             1,513,913
Amortization of transaction costs related to debt financing   65,310                   130,313
Stock based compensation   139,793                  115,803
Tax recovery on warrant expiry   (87,682)       -
Other financing gain   (134,942)       (54,702)
Unrealized foreign exchange (gain) loss   (53,507)                   12,079
Provision for bad debt   63,115       90,845
Interest accretion   222,159                 92,484
    3,520,343              682,339
             
Changes in non-cash working capital balances            
  Accounts receivable and unbilled accounts receivable   (3,598,762)       653,236
  Prepaid expenses   165,635       (154,389)
  Inventory   -                    19,882
  Other assets   (339,752)       -
  Other receivables   (91,211)       (53,338)
  Accounts payable and accrued liabilities   767,762       945,147
  Income taxes payable   (686,921)       19,213
  Deferred revenue   (1,418,421)       (201,263)
               
Cash flows provided by (used in) operating activities   (1,681,327)       1,910,827
             
Cash flow from investing activities            
Purchase of property and equipment   (711,684)       (241,177)
Capitalized development costs   (3,455,981)               (1,869,120)
Acquisition of assets and liabilities from Medrium   -       (1,761,880)
Cash flows used in investing activities   (4,167,665)       (3,872,177)
             
Cash flow from financing activities            
Proceeds from line of credit borrowing   330,000       -
Repayment of line of credit (net of borrowings)   -       (280,000)
Proceeds from convertible debt financing (net of costs)   4,705,723       -
Proceeds from term loan (net of costs)   1,946,850       3,374,983
Repayment of term loans   (882,087)       (1,886,917)
Proceeds from leasehold inducement   120,000       -
Repayment of finance lease obligations   (88,486)       (230,724)
Cash flows provided by financing activities   6,132,000       977,342
             
Foreign exchange losses on cash in foreign currency   9,714       17,660
             
Net increase (decrease) in cash   292,722       (966,348)
Cash and cash equivalents, beginning of period   3,199,058              4,165,406
             
Cash and cash equivalents, end of period $ 3,491,780     $ 3,199,058
             

OVERALL PERFORMANCE, RESULTS OF OPERATIONS AND FINANCIAL CONDITION

                         
  Q4 Year Q1 Q2 Q3 Q4 Year Q1 Q2 Q3 Q4 Year
In $ 000's 
(Except per Share
Amounts)
Ended Ended Ended Ended Ended Ended Ended Ended Ended Ended Ended Ended

March
31,
2011
March
31,
2011
June 30,
2011
Sept 30,
2011
Dec 31,
2011
March
31,
2012
March
31,
2012
June 30,
2012
Sept 30,
2012
Dec 31,
2012
March
31,
2013
March
31,
2013
                         
Recurring Revenue $2,452 $10,679 $2,463 $2,367 $2,473 $2,889 $10,192 $ 2,705 $ 2,665 $ 2,625 $2,606 $10,600
                         
Non-Recurring
Revenue
1,901 6,695 1,342 1,439 2,620 2,486 7,888 2,856 2,403 2,471 2,594 10,324
                         
Revenue 4,353 17,374 3,805 3,807 5,093 5,376 18,080 5,561 5,068 5,096 5,200 20,925
                         
Software business
revenue
3,879 14,780 3,344 3,382 4,679 5,017 16,422 5,480 4,993 5,014 5,145 20,633
                         
Gross Profit 3,675 14,047 3,175 2,961 4,384 4,509 15,030 4,940 4,570 4,336 4,736 18,582
                         
Operating
Expenses
3,870 14,466 3,500 3,225 4,369 4,804 15,897 4,516 4,040 3,949 4,784 17,290
                         
Adjusted EBITDA
(non-IFRS
measure)
384 1,736 35 93 917 231 1,275 916 962 828 1,028 3,733
                         
Operating Income
(Loss) for the
Period
(195) (419) (325) (263) 16 (295) (868) 425 529 387 (48) 1,293
                         
Income (Loss) and
Comprehensive
Income (Loss)
(266) (989) (425) (353) (155) (285) (1,218) 250 624 227 893 1,993
                         
Income (Loss) and
Comprehensive
Income (Loss) per
Common Share -
Basic and Diluted
$(0.00) $(0.01) $(0.00) $(0.00) $(0.00) $(0.01) $(0.02) $0.00 $0.01 $0.00 $0.01 /
$0.01
$0.03 /
$0.03
                         
Weighted Avg. #
of Common Shares
- Basic
76,311 75,979 76,311 76,311 76,311 76,311 76,311 76,311 76,311 76,311 76,311 76,311
                         
Weighted Avg. #
of Common Shares
- Diluted
76,311 75,979 76,311 76,311 76,311 76,311 76,311 82,360 90,086 90,083 92,870 92,882
                         
Total Assets $16,216 $16,216 $15,334 $15,042 $17,794 $17,204 $17,204 $17,962 $19,761 $19,059 $24,697 $24,697
                         
Total Long-Term
Liabilities
$6,115 $6,115 $5,819 $5,972 $8,102 $7,434 $7,434 $7,244 $8,421 $7,861 $9,790 $9,790
                         
Total Deferred
Revenue
$7,510 $7,510 $7,588 $7,607 $7,797 $7,309 $7,309 $7,479 $6,605 $5,913 $5,890 $5,890

 

 

 

SOURCE: Nightingale Informatix Corporation

For further information:

Peter Cauley, CFO
Nightingale Informatix Corporation
Tel: 905-307-7870
pcauley@nightingalemd.com

Marc Lakmaaker, Account Executive
The Equicom Group
Tel: 416-815-0700 ext. 248
mlakmaaker@tmxequicom.com

Profil de l'entreprise

Nightingale Informatix Corporation

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.